Please use this identifier to cite or link to this item:
|Title:||Guidelines for diagnosis and management of the cobalamin-related remethylation disorders cblC, cblD, cblE, cblF, cblG, cblJ and MTHFR deficiency|
Couce, Maria L.
la Marca, Giancarlo
Weisfeld-Adams, James D.
Baumgartner, Matthias R.
Rare Inherited Disorders
|Publisher:||Springer Verlag/ Society for the Study of Inborn Errors of Metabolism|
|Citation:||J Inherit Metab Dis. 2017 Jan;40(1):21-48. doi: 10.1007/s10545-016-9991-4. Epub 2016 Nov 30|
|Abstract:||Background: Remethylation defects are rare inherited disorders in which impaired remethylation of homocysteine to methionine leads to accumulation of homocysteine and perturbation of numerous methylation reactions. Objective: To summarise clinical and biochemical characteristics of these severe disorders and to provide guidelines on diagnosis and management. Data sources: Review, evaluation and discussion of the medical literature (Medline, Cochrane databases) by a panel of experts on these rare diseases following the GRADE approach. Key recommendations: We strongly recommend measuring plasma total homocysteine in any patient presenting with the combination of neurological and/or visual and/or haematological symptoms, subacute spinal cord degeneration, atypical haemolytic uraemic syndrome or unexplained vascular thrombosis. We strongly recommend to initiate treatment with parenteral hydroxocobalamin without delay in any suspected remethylation disorder; it significantly improves survival and incidence of severe complications. We strongly recommend betaine treatment in individuals with MTHFR deficiency; it improves the outcome and prevents disease when given early.|
|Description:||PMC Free: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203859/|
|Appears in Collections:||DGH - Artigos em revistas internacionais|
Files in This Item:
|art%3A10.1007%2Fs10545-016-9991-4.pdf||908,76 kB||Adobe PDF||View/Open|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.